Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia

References

• Hirschfeld RMA, Bowden CL, Gitlin MJ, et al. American psychiatric association work group on bipolar disorder. Practice guideline for the treatment of patients with bipolar disorder, Second Edition. APA practice guidelines. Arlington, VA: American Psychiatric Association; 2010.
   Google Scholar
• Connolly KR, Thase ME. The clinical management of bipolar disorder: a review of evidence-based guidelines. Prim Care Companion CNS Disord. 2011;13(4):PCC.10r01097.
   PubMedGoogle Scholar
• Patel KR, Cherian J, Gohil K, et al. Schizophrenia: overview and treatment options. Pharm Ther. 2014;39(9):638–645.
   Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. American psychiatric association work group on schizophrenia. Practice guideline for the treatment of patients with schizophrenia, Second Edition. Arlington, VA: American Psychiatric Association; 2010.
   Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2.
   PubMed Web of Science ®Google Scholar
• Foster A, Gable J, Buckley J. Homelessness in schizophrenia. Psychiatr Clin North Am. 2012;35(3):717–734.
   PubMed Web of Science ®Google Scholar
• Thoma P, Daum I. Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. Psychiatry Clin Neurosci. 2013;67(6):367–383.
   PubMed Web of Science ®Google Scholar
• Llorca PM, Abbar M, Courtet P, et al. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340–340.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Schooler NR, Weedon JC, et al. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry. 2009;70(10):1397–1406.
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen P, Koen L, et al. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2008;30(12):2378–2386.
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842–851.
   PubMed Web of Science ®Google Scholar
• Buckley PF, Schooler NR, Goff DC, et al. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015;41(2):449–459.
   PubMed Web of Science ®Google Scholar
• Kim B, Lee S-H, Choi TK, et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1231–1235.
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74(10):957–965.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609.
   PubMed Web of Science ®Google Scholar
• Offord S, Wong B, Mirski D, et al. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs. oral. J Med Econ. 2013;16(2):231–239.
   PubMedGoogle Scholar
• Lafeuille M-H, Laliberté-Auger F, Lefebvre P, et al. Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry. 2013;13(1):221.
   PubMed Web of Science ®Google Scholar
• Shah A, Xie L, Kariburyo F, et al. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics. Adv Ther. 2018;35(11):1994–2014.
   PubMed Web of Science ®Google Scholar
• Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015;21(9):754–769.
   PubMed Web of Science ®Google Scholar
• Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764–771.
   PubMed Web of Science ®Google Scholar
• Cloutier M, Greene M, Guerin A, et al. The economic burden of bipolar I disorder in the United States in 2015. J Affect Disord. 2018;226:45–51.
   PubMed Web of Science ®Google Scholar
• Lauriello J, Campbell AR. Pharmacotherapy for schizophrenia: long-acting injectable antipsychotic drugs; 2021 [updated 2020 Oct 5; cited 2021 Oct 12]. Available from: https://www-uptodate-com/contents/pharmacotherapy-for-schizophrenia-long-acting-injectable-antipsychotic-drugs.
   Google Scholar
• Skrepnek GH. Regression methods in the empirical analysis of health care data. J Manag Care Pharm. 2005;11(3):240–251.
   PubMedGoogle Scholar
• Skrepnek GH, Olvey EL, Sahai A. Econometric approaches in evaluating costs and outcomes within pharmacoeconomic analyses. Pharm Policy Law. 2012;14(1):105–122.
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619.
   PubMed Web of Science ®Google Scholar
• Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4):1049–1060.
   PubMed Web of Science ®Google Scholar
• Pan W, Connett JE. Selecting the working correlation structure in generalized estimating equations with application to the lung health study. Statistica Sinica. 2002;12:475–490.
   Web of Science ®Google Scholar
• Huber P. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. Vol. 1; Berkeley and Los Angeles: University of California Press; 1967. p. 221–33.
   Google Scholar
• White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48(4):817–838.
   Web of Science ®Google Scholar
• Eicker F. Limit theorems for regression with unequal and dependent errors. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, Berkeley; 1967. p. 59–82.
   Google Scholar
• Tutzauer F. On the sensible application of familywise alpha adjustment. Human Comm Res. 2003;29(3):455–463.
   Web of Science ®Google Scholar
• O’Keefe DJ. Searching for a defensible application of alpha-adjustment tools. Human Comm Res. 2003;29(3):464–468.
   Web of Science ®Google Scholar
• Matsunaga M. Familywise error in multiple comparisons: disentangling a knot through a critique of O’Keefe’s arguments against alpha adjustment. Comm Methods Measures. 2007;1(4):243–265.
   Google Scholar
• Rubin M. When to adjust alpha during multiple testing: a consideration of disjunction, conjunction, and individual testing. Synthese. 2021;199(3–4):10969–11000.
   Web of Science ®Google Scholar
• Broder MS, Greene M, Chang E, et al. Health care resource use, costs, and diagnosis patterns in patients with schizophrenia and bipolar disorder: real-world evidence from US claims databases. Clin Ther. 2018;40(10):1670–1682.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–693.
   PubMed Web of Science ®Google Scholar
• Kurdyak P, Vigod SN, Newman A, et al. Impact of physician follow-up care on psychiatric readmission rates in a population-based sample of patients with schizophrenia. Psychiatr Serv. 2018;69(1):61–68.
   PubMed Web of Science ®Google Scholar
• Okumura Y, Sugiyama N, Noda T. Timely follow-up visits after psychiatric hospitalization and readmission in schizophrenia and bipolar disorder in Japan. Psychiatry Res. 2018;270:490–495.
   PubMed Web of Science ®Google Scholar
• The National Committee for Quality Assurance. Follow-up after emergency department visit for mental illness (FUM). NCQA website; 2021 [cited 2021 Feb 9]. Available from: https://www.ncqa.org/hedis/measures/follow-up-after-emergency-department-visit-for-mental-illness/.
   Google Scholar
• The National Committee for Quality Assurance. Follow-up after hospitalization for mental illness (FUH). NCQA website; [cited 2021 Feb 9]. Available from: https://www.ncqa.org/hedis/measures/follow-up-after-hospitalization-for-mental-illness/.
   Google Scholar
• Marcus SC, Chuang C-C, Ng-Mak DS, et al. Outpatient follow-up care and risk of hospital readmission in schizophrenia and bipolar disorder. Psychiatr Serv. 2017;68(12):1239–1246.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
   PubMed Web of Science ®Google Scholar